The Striking Visualization of Bludigo® in Action

Indigotindisulfonate (indigo carmine) is a dye excreted by the kidneys through tubular secretion and enhances visualization of the ureteral orifices by its deep blue color.1

Urine jet post-Bludigo® application1

Surgeons rated their overall satisfaction with Bludigo® 5 mL1

Overall satisfaction with indigo carmine (score of 1 or 2) was 89.8% with the high dose1

Physician's Response to Statement:
"Compared to the saline treatment, my ability to assess ureter patency was improved after the addition of indigo carmine."
indigo carmine
5 mL (high dose)
1 Strongly agree
36 (73.5%)
2 Agree
8 (16.3%)
3 Neither agree nor disagree
3 (6.1%)
4 Disagree
5 Strongly disagree
2 (4.1%)
Overall satisfaction (score of 1 or 2)
44 (89.8%)

Nearly 9 out of 10 physicians reported overall satisfaction with Bludigo® visualization improvement1

These results are not included in the approved Bludigo® package insert.

BLUDIGO® (indigotindisulfonate sodium injection, USP)


BLUDIGO® is a diagnostic dye indicated for use as a visualization aid in the cystoscopic assessment of the integrity of the ureters in adults following urological and gynecological open, robotic, or endoscopic surgical procedures.



BLUDIGO® is contraindicated in patients with known hypersensitivity to indigotindisulfonate or any of its components.


Cardiovascular Reactions: Severe or life-threatening cardiovascular reactions including cardiac arrest, arrhythmia, asystole, atrioventricular block second degree, hypotension, elevation in blood pressure, bradycardia, and tachycardia have been reported. Closely monitor blood pressure and cardiac rhythm during and following the BLUDIGO® injection. Interrupt administration if reactions are observed.

Hypersensitivity Reactions: Serious anaphylactic reactions with hypotension, dyspnea, bronchospasm, urticaria, or erythema have been reported. Monitor patients for anaphylactic reactions and have emergency equipment and trained personnel readily available.

Interference with Oximetry Measurements: Anesthesiologists should be aware of the potential for artifactual reduction in SpO2 when anesthetized patients are administered BLUDIGO®.


Renal Impairment: BLUDIGO® is not recommended for use in patients with eGFR<30 mL/min.

Pediatric Use: The safety and effectiveness of BLUDIGO® have not been established in pediatric patients.

Pregnancy and Lactation: Please consult the Full Prescribing Information before using BLUDIGO® in a patient that is lactating, pregnant, or may be pregnant.


The recommended dose for BLUDIGO® is 5 mL given intravenously over 1 minute.


  • Monitor blood pressure and cardiac rhythm during and following the injection.
  • Use immediately after opening ampule.
  • Withdraw the contents of the ampule through a 5 micron or smaller filter straw/filter needle to ensure that the withdrawn solution contains no particulates. The withdrawn solution should be inspected visually for particulate matter and discoloration prior to administration.
  • Do not administer with infusion assemblies used with other diluents or drugs.
  • Discard any unused portion.


Clinical Trial Experience: The most common adverse reactions (1%) associated with BLUDIGO® in clinical trials were: constipation, nausea, vomiting, abdominal pain, pyrexia, ALT increase, and dysuria.

Postmarketing Experience: The following adverse reactions have been identified following the use of indigotindisulfonate sodium injection products:

  • Cardiovascular disorders: cardiac arrest, arrhythmia, asystole, atrioventricular block second degree, hypotension, elevation in blood pressure, bradycardia, tachycardia
  • General disorders and administration site conditions: injection site discoloration
  • Immune system disorders: anaphylactic reactions with hypotension, dyspnea, bronchospasm, urticaria, erythema

Please see the full Prescribing Information for additional Important Safety Information.

To report SUSPECTED ADVERSE REACTIONS, contact PROVEPHARM Inc at 1–833-727-6556 or FDA at 1-800-FDA-1088 or

References: 1. Data on file. PVP-10ICO1 clinical study report. Newark, NJ: Provepharm, Inc.; 2024.